CAB7-3

CAB7-3 is an orally effective HBV capsid assembly modulator that demonstrates excellent antiviral potency. It inhibits HBVDNA with an EC50 of 70 nM and has a CC50 of 32.3 μM. The compound exhibits significant anti-HBV activity across various cell models, with EC50 values of 70 μM in HBV-integrated HepDES19 cells, 1 nM in tetracycline-induced HepAD38 cells, and 2 nM in HBV-infected HLCZ01 cells. In vivo, CAB7-3 effectively reduces hepatic HBV core protein levels and suppresses viral replication. It shows good drug-like properties and safety, making it suitable for hepatitis B virus research.